Related Experiment Video
Updated: May 15, 2026

Dissecting Multi-protein Signaling Complexes by Bimolecular Complementation Affinity Purification (BiCAP)
Published on: June 15, 2018
Adaptor protein complex of FRS2β and CIN85/CD2AP provides a novel mechanism for ErbB2/HER2 protein downregulation
Yuriko Minegishi1, Yoshio Shibagaki, Anna Mizutani
1Division of Systems Biomedical Technology, The University of Tokyo, Tokyo, Japan.
Abstract:
Overexpression of the ErbB2/HER2 receptor tyrosine kinase contributes to tumorigenesis. However, mechanisms regulating ErbB2 protein levels remain largely unclear. Here, we identified novel mechanisms of ErbB2 downregulation. ErbB2 constitutively binds to an adaptor protein FRS2β. We found that FRS2β bound to CD2AP and CIN85, which induces endosomal trafficking that targets lysosomes. FRS2β colocalized with CIN85 in the cytoplasm. Expression of wild type FRS2β but not its CIN85 non-binding mutant, downregulated the ErbB2 protein and inhibited anchorage-independent cell growth. Moreover, the E3 ubiquitin-protein ligase Cbl was contained within a complex of FRS2β and CIN85. Knockdown of both CIN85 and CD2AP or of Cbl, or treatment with lysosomal degradation inhibitors diminished FRS2β downregulation of ErbB2. In addition, knockdown of endogenous FRS2β caused upregulation of ErbB2 in primary neural cells. Finally, immunohistochemical analysis showed that human breast cancer tissues that overexpress ErbB2 expressed low levels of FRS2β. Thus, an FRS2β-CIN85/CD2AP-Cbl axis for downregulation of ErbB2 may regulate ErbB2 protein levels in physiological and pathological settings. Molecular targeting drugs that can increase or stabilize the ErbB2-FRS2β-CIN85/CD2AP-Cbl axis may have promise for the control of ErbB2-overexpressing tumors.
Insights
Researchers discovered a new pathway involving FRS2β, CIN85, CD2AP, and Cbl that downregulates ErbB2 (HER2) protein. This finding offers potential new targets for treating ErbB2-overexpressing cancers.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- ErbB2 (HER2) receptor tyrosine kinase overexpression drives tumorigenesis.
- Mechanisms controlling ErbB2 protein levels are not fully understood.
Purpose of the Study:
- To identify novel mechanisms regulating ErbB2 protein levels.
- To elucidate the role of adaptor protein FRS2β in ErbB2 downregulation.
Main Methods:
- Investigated protein-protein interactions using co-immunoprecipitation.
- Assessed protein levels via Western blotting.
- Utilized knockdown experiments and pharmacological inhibitors.
- Performed immunohistochemical analysis on human breast cancer tissues.
Main Results:
- Identified a novel FRS2β-CIN85/CD2AP-Cbl complex involved in ErbB2 downregulation.
- FRS2β mediates lysosomal trafficking and degradation of ErbB2.
- Knockdown of FRS2β components or Cbl impaired ErbB2 downregulation.
- Low FRS2β expression correlated with high ErbB2 levels in breast cancer.
Conclusions:
- An FRS2β-CIN85/CD2AP-Cbl axis regulates ErbB2 protein levels.
- This axis represents a potential therapeutic target for ErbB2-overexpressing tumors.
More Related Videos
10:16SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
Published on: January 6, 2017
10:50Using In Vitro Fluorescence Resonance Energy Transfer to Study the Dynamics Of Protein Complexes at a Millisecond Time Scale
Published on: March 14, 2019
Related Concept Videos
Anaphase Promoting Complex
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Directing Proteins to the Rough Endoplasmic Reticulum
Amplifying Signals via Enzymatic Cascade
GPCR Desensitization